13 Best Revenue Growth Stocks to Buy Right Now

Page 12 of 12

1. Legend Biotech Corp (NASDAQ:LEGN)

Price Target Upside: 267.03%

Number of Hedge Fund Holders: 28

Legend Biotech Corp (NASDAQ:LEGN) is one of the Best Revenue Growth Stocks to Buy Right Now.

In a board shakeup last month, Legend Biotech Corp (LEGN) appointed chairman and executive director of a major shareholder, GenScript, Robin Meng, as a Class III director to serve until the company’s 2026 annual general meeting, replacing outgoing director Li Zhu.

Directors Li Zhu and Yau Wai Man Philip resigned from the board, with Legend Biotech stating that the departures were not related to any dispute over operations or policies.

Earlier in the month, H. C. Wainwright lowered the price target on the stock to $50 from $60, while TD Cowen downgraded the stock to Hold from Buy, with a price target of $21.

On January 21, Legend Biotech reported preliminary net trade sales of approximately $555 million for its multiple myeloma cell therapy, CARVYKTI, for the quarter ended Dec. 31, 2025.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications.

While we acknowledge the potential of LEGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LEGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Software Infrastructure Stocks to Buy According to Hedge Funds and 11 Best Stocks You’ll Wish You Bought Sooner.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 12 of 12